Form 4: Capricor Therapeutics Director Philip J. Gotwals Acquires Stock Options

Director Philip J. Gotwals of Capricor Therapeutics acquired stock options for 19,850 shares on January 2, 2025, with varying vesting schedules.

Summary

• Philip J. Gotwals, a director at Capricor Therapeutics, was granted stock options to purchase a total of 19,850 shares of common stock on January 2, 2025.
• These options are divided into three grants: 11,940 shares vesting monthly starting February 1, 2025, 2,160 shares fully vested immediately, and 5,750 shares fully vested immediately.
• All options have an exercise price of $14.96 and expire on January 2, 2035.
• The options are subject to early exercise, but shares purchased before vesting are considered restricted stock and subject to repurchase by the company if the director's service terminates before vesting.

Sentiment

Score: 7

Explanation: The document reflects a routine grant of stock options to a director, which is generally positive for aligning interests but not a major market-moving event.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule for a portion of the options encourages continued service by the director.

Risks

• The early exercise feature of the options could lead to the company repurchasing shares if the director leaves before vesting, potentially impacting the company's cash flow.
• The value of the options is dependent on the future performance of the company's stock price.

Future Outlook

The director's stock options will vest over time, aligning their interests with the long-term success of the company.

Industry Context

Stock option grants are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for compensating board members in the biotechnology industry, similar to companies like Amgen and Gilead Sciences.
• The vesting schedule of the options is typical, with a mix of immediate and time-based vesting, which is comparable to practices at other biotech firms.
• The exercise price of $14.96 is a key factor, and its value will depend on the future performance of Capricor's stock, similar to how stock options are valued at companies like Regeneron and Biogen.

Stakeholder Impact

• The stock option grants align the director's interests with those of shareholders, potentially leading to better decision-making.
• The vesting schedule may encourage the director's continued service to the company.

Key Dates

Keywords

stock options, Capricor Therapeutics, director, insider trading, equity compensation, vesting, Form 4